<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943136</url>
  </required_header>
  <id_info>
    <org_study_id>Papaya for impetigo</org_study_id>
    <nct_id>NCT01943136</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philippine Dermatological Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Luke's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philippine Dermatological Society</source>
  <oversight_info>
    <authority>Philippines: Bureau of Food and Drugs</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an investigator-blinded, patient-blinded, assessor-blinded,
      parallel-group, randomized clinical trial. It aims to evaluate the efficacy of one-week
      twice-daily application of topical papaya leaf extract ointment compared to mupirocin
      ointment in achieving clinical cure among patients with impetigo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical clearance after 1 week of treatment</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to clinical clearance</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score in the 6-point grading system</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The 6-point grading system will assess clinical response based on each of the following six paramaters. One point will be assigned for each of the following parameters present in a patient, with the maximum possible score on this grading system being 6. A patient need not satisfy all six parameters. A decrease in score on this grading system compared to baseline will indicate clinical improvement, while an increase in score will indicate clinical worsening.
erythema
edema
vesiculation
pustulation
crusting
scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in size of lesion compared to baseline</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or absence of recurrence on any part of the body 2 weeks after starting treatment</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or absence of adverse events during treatment</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>papaya 1% extract ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>papaya 1% extract ointment twice a day for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mupirocin 2% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mupirocin 2% ointment twice a day for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>papaya 1% extract ointment</intervention_name>
    <arm_group_label>papaya 1% extract ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mupirocin 2% ointment</intervention_name>
    <arm_group_label>mupirocin 2% ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Filipino patients aged 1 year and above with primary impetigo, limited to
             less than or equal to 1% BSA, and involving only one body area

        Exclusion Criteria:

          -  Extensive impetigo (&gt;1% BSA), affecting more than one body area

          -  Systemic involvement (lymphadenopathy, fever, sepsis)

          -  Chronic comorbidities like diabetes mellitus, malignancy, chronic venous
             insufficiency

          -  Concurrent immunosuppressive therapy

          -  Patients ≤ 1 year

          -  Pregnant &amp; lactating patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mia Angela C Verzosa, MD</last_name>
    <role>Study Director</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pearl Weena Marie E Sabido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janine L. Quijano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janine L. Quijano, MD</last_name>
    <email>janinequijanoMD@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>NCR</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quijano</last_name>
      <email>janinequijanoMD@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <reference>
    <citation>Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2012 Jan 18;1:CD003261. doi: 10.1002/14651858.CD003261.pub3. Review.</citation>
    <PMID>22258953</PMID>
  </reference>
  <reference>
    <citation>Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect. 2009 Sep;59 Suppl 1:S4-16. doi: 10.1016/S0163-4453(09)60003-7. Review.</citation>
    <PMID>19766888</PMID>
  </reference>
  <reference>
    <citation>Witte W, Cuny C, Klare I, Nübel U, Strommenger B, Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int J Med Microbiol. 2008 Jul;298(5-6):365-77. doi: 10.1016/j.ijmm.2007.10.005. Epub 2008 Mar 5. Review.</citation>
    <PMID>18325835</PMID>
  </reference>
  <reference>
    <citation>Martin KW, Ernst E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother. 2003 Feb;51(2):241-6. Review.</citation>
    <PMID>12562687</PMID>
  </reference>
  <reference>
    <citation>Pieper B, Caliri MH. Nontraditional wound care: A review of the evidence for the use of sugar, papaya/papain, and fatty acids. J Wound Ostomy Continence Nurs. 2003 Jul;30(4):175-83. Review.</citation>
    <PMID>12851592</PMID>
  </reference>
  <reference>
    <citation>Hewitt H, Whittle S, Lopez S, Bailey E, Weaver S. Topical use of papaya in chronic skin ulcer therapy in Jamaica. West Indian Med J. 2000 Mar;49(1):32-3.</citation>
    <PMID>10786448</PMID>
  </reference>
  <reference>
    <citation>Owoyele BV, Adebukola OM, Funmilayo AA, Soladoye AO. Anti-inflammatory activities of ethanolic extract of Carica papaya leaves. Inflammopharmacology. 2008 Aug;16(4):168-73. doi: 10.1007/s10787-008-7008-0.</citation>
    <PMID>18759075</PMID>
  </reference>
  <reference>
    <citation>Dawkins G, Hewitt H, Wint Y, Obiefuna PC, Wint B. Antibacterial effects of Carica papaya fruit on common wound organisms. West Indian Med J. 2003 Dec;52(4):290-2.</citation>
    <PMID>15040064</PMID>
  </reference>
  <reference>
    <citation>Iliev D, Elsner P. Generalized drug reaction due to papaya juice in throat lozenges. Dermatology. 1997;194(4):364-6.</citation>
    <PMID>9252760</PMID>
  </reference>
  <reference>
    <citation>Niinimäki A, Reijula K, Pirilä T, Koistinen AM. Papain-induced allergic rhinoconjunctivitis in a cosmetologist. J Allergy Clin Immunol. 1993 Sep;92(3):492-3.</citation>
    <PMID>8360400</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Philippine Dermatological Society</investigator_affiliation>
    <investigator_full_name>Pearl Weena Marie Sabido</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>impetigo</keyword>
  <keyword>papaya extract ointment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
